<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/62A9A55D-8318-4DBA-9F54-1563897BAA9B"><gtr:id>62A9A55D-8318-4DBA-9F54-1563897BAA9B</gtr:id><gtr:name>Bruker Corporation</gtr:name><gtr:address><gtr:line1>19 Fortune Drive</gtr:line1><gtr:line2>Manning Park</gtr:line2><gtr:postCode>01821</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/087B9388-D675-433D-9F2E-73DA7C8E11D1"><gtr:id>087B9388-D675-433D-9F2E-73DA7C8E11D1</gtr:id><gtr:name>Fera Science Limited</gtr:name><gtr:address><gtr:line1>17 Rochester Row</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SW1P 1QT</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:department>Chemistry</gtr:department><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8319F78A-DCBD-49F6-BE00-78E1CD75CDA9"><gtr:id>8319F78A-DCBD-49F6-BE00-78E1CD75CDA9</gtr:id><gtr:name>University of York</gtr:name><gtr:address><gtr:line1>Heslington</gtr:line1><gtr:line4>York</gtr:line4><gtr:line5>North Yorkshire</gtr:line5><gtr:postCode>YO10 5DD</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/62A9A55D-8318-4DBA-9F54-1563897BAA9B"><gtr:id>62A9A55D-8318-4DBA-9F54-1563897BAA9B</gtr:id><gtr:name>Bruker Corporation</gtr:name><gtr:address><gtr:line1>19 Fortune Drive</gtr:line1><gtr:line2>Manning Park</gtr:line2><gtr:postCode>01821</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/087B9388-D675-433D-9F2E-73DA7C8E11D1"><gtr:id>087B9388-D675-433D-9F2E-73DA7C8E11D1</gtr:id><gtr:name>Fera Science Limited</gtr:name><gtr:address><gtr:line1>17 Rochester Row</gtr:line1><gtr:city>London</gtr:city><gtr:postCode>SW1P 1QT</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E33E8B7A-75CF-4D5F-945B-BAD40BA3E224"><gtr:id>E33E8B7A-75CF-4D5F-945B-BAD40BA3E224</gtr:id><gtr:firstName>S</gtr:firstName><gtr:surname>Duckett</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/954AC80A-47B7-4F47-A3D0-7FE79078703C"><gtr:id>954AC80A-47B7-4F47-A3D0-7FE79078703C</gtr:id><gtr:firstName>Gary</gtr:firstName><gtr:surname>Green</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FH029575%2F1"><gtr:id>FB7C4D2E-67A6-4339-A27E-ED802D0CF7CA</gtr:id><gtr:title>Signal Amplification in NMR and MRI using hyperpolarised compounds</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>EP/H029575/1</gtr:grantReference><gtr:abstractText>The NMR Centre and the Neuroimaging Centre at the University of York have conducted a programme of work that has demonstrated that one of the fundamental limitations of conventional Nuclear Magnetic Resonance (NMR) and Magnetic Resonance Imaging (MRI) techniques can be dramatically overcome. NMR is the most popular method for performing analytical and structural chemistry and MRI is the technique of choice for carrying out non-invasive imaging in humans. Even though the global markets for these techniques exceeds 6billion annually, as identified in a recent US report to Congress, both technologies are limited in application due to poor sensitivity. A process termed hyperpolarisation, developed in York throughout the last decade, allows these limitations to be overcome. We have recently shown that 0.5 seconds worth of data collection equates to 58 days on the conventional device.In laymen's terms, both NMR and MRI deal with the probing of the magnetic behaviour of nuclei within molecules. These nuclei behave like bar magnets and therefore can either have a north or south seeking orientation. Parahydrogen is simply a reaction feedstock where rather than having a mixture of such orientations, we start with a pure magnetic form. We have established a new route to utilising this feedstock in MR studies. The parahydrogen simply acts like a radiator which when brought into contact with its surroundings warms the room. In this case, the result is a potential 31,000 increase in detected signal strength. The information obtained through MIR studies is well established as providing critical information related to diagnosis and treatment in the health field. The breakthrough in sensitivity enhancement offers opportunities for a step change in modern healthcare and in high resolution NMR markets. This is achieved without the chemical modification of a material and it can employ substances that are native to the body. We therefore expect that it will not suffer from the toxicological problems associated with gadolinium contrast agents and PET and hence be well received by the medical community and laymen alike.Please see Proposal Form for details</gtr:abstractText><gtr:potentialImpactText>Magnetic resonance imaging (MRI) is widely and powerfully used in front-line healthcare. The importance of MRI to modern medicine is such that any advances which increase its diagnostic availability will lead to major and lasting gains, with improvements in the selectivity and the sensitivity of MRI contrast agents particularly opening up major new healthcare possibilities. Given the multidisciplinary nature of MRI, future advances will rely on teams of scientists, biomedical scientists and clinicians working closely together in an interdisciplinary manner that come from companies and Universities. Here we seek to achieve this by applying a revolutionary new technology developed at the University of York. MRI works by detecting the radio frequency signals which result from nuclei undergoing a magnetic spin state alignment change. These signals, however, are very weak, severely limiting the information available from MRI. Information enhancement can be achieved by using a contrast agent. Indeed, over 1.4 million MRI scans were performed in the NHS in 2008 where almost one third required an injected contrast agent to provide useful clinical information. The contrast agents in current widespread use are based on gadolinium. These agents are relatively sensitive giving clinician's good anatomical information, but offer no biochemical selectivity. They also suffer from potential toxicity issues. There is therefore a widely recognised and urgent need for new contrast agents and, in particular, for new agents offering significant increases in sensitivity. Increases in sensitivity will lead to major benefits in front-line healthcare which include, for example, reductions of the size of MRI scanners which in itself would greatly expand the accessibility and availability of MRI. Advances in contrast agent selectivity and specificity would also give a step change in the quality of clinically useful information available from imaging. In this context, hyperpolarised contrast agents have the potential to revolutionise magnetic resonance methods such as MRI through unrivaled gains in contrast agent sensitivity. Already, hyperpolarised xenon is used medically in lung imaging. For example, while hardware developments such as increasing magnet size in high resolution NMR spectroscopy over the last 20 years have improved the strength of the detected signal by just over one order of magnitude, hyperpolarisation can increase sensitivity by five orders of magnitude in a single step with no changes in the detection hardware. Significantly, the ability to hyperpolarise molecules of biological interest opens up the possibility of major increases in not only sensitivity both also in selectivity. It is here where York has made significant breakthroughs by utilising parahydrogen to generate hyperpolarised contrast agents simply and easily. The advantage of York's new method is that it allows the rapid production of large amounts of hyperpolarised agents without changing their molecular structure (a significant advantage over other hyperpolarisation methods and dynamic nuclear polarisation techniques where the method of contrast agent generation is limited in either amount/speed of sample and/or range of materials that can be hyperpolarised). Using the York technology, the in vivo chemical functionality of the molecule will be retained which offers the potential to create highly sensitive and highly specific contrast agents reliably and inexpensively. The benefits of the hyperpolarisation approach for improving healthcare are not restricted to imaging. In its high resolution version it enables the detailed characterisation of molecules in solution, leading to direct applications for better drug discovery product screening, sample characterisation, stability studies, and enzyme structure determinations. The impact of this methods therefore spans many areas of science, but here we seek to primarily develop the MRI context.</gtr:potentialImpactText><gtr:fund><gtr:end>2012-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2010-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>76490</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Using SABRE to aid in the study of biologically relevant molecules</gtr:description><gtr:id>F03816D0-8D62-41DC-8702-2B4A13E14DA3</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>5457c2b6c9ccc5.12874939-1</gtr:outcomeId><gtr:partnerContribution>Knowledge and materials</gtr:partnerContribution><gtr:piContribution>We have worked with AstraZeneca on the application of SABRE methods to aid in the characterisation and probing
of small molecules of biological relevance</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Bruker Corporation</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Bruker BioSpin</gtr:department><gtr:description>Bruker BioSpin</gtr:description><gtr:id>C9FE5B1E-6C8F-4C4F-A48B-EFACE8D53EC0</gtr:id><gtr:impact>Bruker now sell a parahydrogen generator. A beta test version of the polariser in on test with 5 international research groups.</gtr:impact><gtr:outcomeId>5457c0f7a370d7.66337813-1</gtr:outcomeId><gtr:partnerContribution>Bruker have provided access to equipment and engineering. They have provided legal support for patents</gtr:partnerContribution><gtr:piContribution>We have worked with Bruker to produce a parahydrogen generator, a device for the preparation of hyperpolarised samples and a flow probe for the detection of hyperpolarised signals</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Using SABRE to aid molecular characterisation</gtr:description><gtr:id>B65005DC-B40F-468F-82BA-8F7EE0676671</gtr:id><gtr:impact>Publications</gtr:impact><gtr:outcomeId>5457c219b64f84.20843685-1</gtr:outcomeId><gtr:partnerContribution>They provide knowledge and materials.</gtr:partnerContribution><gtr:piContribution>GlaxoSmithKline has supported two studentships to drive forward the SABRE research. They are interested in using it to probe
pharamaceutical products</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fera Science Limited</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Using parahydrogen to probe small molecules</gtr:description><gtr:id>81FF3978-7DF1-402A-84E2-7270E2E683BF</gtr:id><gtr:impact>Publicatons</gtr:impact><gtr:outcomeId>5457c35b8ba542.56819088-1</gtr:outcomeId><gtr:partnerContribution>Knowledge and Materials</gtr:partnerContribution><gtr:piContribution>We worked with FERA to develop methods to characterise trace amounts of organic materials that are relevant to food.</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>German-UK MR Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7A690278-51E4-4236-97C8-9082DFD8CF89</gtr:id><gtr:impact>Invited key-note talk at international meeting.</gtr:impact><gtr:outcomeId>56c5f1d5455bf2.97984687</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.chemie.tu-darmstadt.de/gdch-fgmr2015/fgmr_2015/index.en.jsp</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>5th Australian Organometallics Meeting (Sydney)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>07EDDDC0-1459-450C-8EC0-9232CF8728C8</gtr:id><gtr:impact>70 academics, postdocs and research students attended a research presentation, which sparked questions and discssion afterwards

Subsequent joint ARC grant with B Messerle (Sydney)</gtr:impact><gtr:outcomeId>5457c5b0a05252.44996066</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BioNMR workshop Weizmann Institute.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B33F1701-86A4-4C9B-8F90-1F67D0E3566D</gtr:id><gtr:impact>Over 50 people attended a presentation which sparked questions and discussion afterwards 

Over 15 research groups worldwide have adopted our methods</gtr:impact><gtr:outcomeId>5457d8bcd92e36.60706614</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:url>http://www.weizmann.ac.il/weizsites/bionmr/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Imaging in 2020 VII, Bridging Molecular Imaging and Therapy, Jackson Hole USA.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6D3F218C-076F-41D2-B621-83C281837855</gtr:id><gtr:impact>people attended a presentation which sparked questions and discussion afterwards

15 research groups worldwide have adopted our methods</gtr:impact><gtr:outcomeId>5457cf08e69c68.92777943</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MRC Hyperpolarised MRI workshop</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E368A76D-7D54-4E8A-A84C-F672B48F6A4C</gtr:id><gtr:impact>Workshop to consider progress in hyperpolarisation that will lead to clinical use</gtr:impact><gtr:outcomeId>56c5f0f32a3f88.01123536</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Experimental Nuclear Magnetic Resonance Conference (ENC), Daytona Beach USA.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>45B169CE-D543-444A-87E8-DE15055BB13F</gtr:id><gtr:impact>Over 100 people attended a presentation which sparked questions and discussion afterwards

Over 15 research groups worldwide have adopted our methods</gtr:impact><gtr:outcomeId>5457c71deb8311.71438396</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.enc-conference.org/</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wellcome Trust, Next Generation Brain Imaging Technologies, London, UK.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8EFC030C-5B62-4F38-A825-5AC03579A645</gtr:id><gtr:impact>people attended a presentation which sparked questions and discussion afterwards

Funding awarded to take methods forward.</gtr:impact><gtr:outcomeId>5457cf895004c4.06526927</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk, ISMAR, Rio de Janerio, Brazil</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EDF6F881-EF45-4184-8F45-7D8580222D8C</gtr:id><gtr:impact>people attended a presentation which sparked questions and discussion afterwards

Over 15 research groups worldwide have adopted our methods</gtr:impact><gtr:outcomeId>5457cfefb05304.04529314</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker, Euromar, Dublin, Eire.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7BC722B4-42CC-4183-A0F3-C9AB4FF2A9F0</gtr:id><gtr:impact>Over 100 people attended a presentation which sparked questions and discussion afterwards 

Over 15 research groups worldwide have adopted our methods</gtr:impact><gtr:outcomeId>5457d0349b5594.25978031</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>York Hyperpolarisation Symposium (2 Day)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C5718CF5-D903-4C87-8BDC-A11009E64CB3</gtr:id><gtr:impact>Series of 20 talks over 2 days</gtr:impact><gtr:outcomeId>58c18c85d1fbe9.93377295</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Rank Prize Symposium</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D6DF296F-AAE0-4EE7-8173-30FEE90306C4</gtr:id><gtr:impact>I contributed to a workshop aimed at driving forward change in chemical detection

Over 15 research groups worldwide have adopted our methods</gtr:impact><gtr:outcomeId>5457c9d1d38669.36754828</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.rankprize.org/index.php/symposia/general</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Chemistry Meets Imaging: Molecular Routes to Enhance Contrast</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2A34F5D1-8EB4-4536-B376-7E41320B907F</gtr:id><gtr:impact>Presentation at international meeting at Duke, USA</gtr:impact><gtr:outcomeId>56c5f324a4d116.03835072</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://cmbi.duke.edu/conferences/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Opening National Centre of Hyperpolarised MRI</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F8A0EA2A-81BF-49BA-8B29-715DD50CA908</gtr:id><gtr:impact>Scientific talk on developments in SABRE hyperpolarisation.</gtr:impact><gtr:outcomeId>58c18d03e37667.08652013</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Using SABRE to improve NMR and MRI</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>72D60704-9819-49B6-9845-AAC5232230EB</gtr:id><gtr:impact>Talk given in Paris</gtr:impact><gtr:outcomeId>58c18a1098f9e5.62583301</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>7th Conference on Field Cycling NMR Relaxometry</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>11B63B61-314F-4563-95B8-65B9274C5B6D</gtr:id><gtr:impact>People attended a presentation which sparked questions and discussion afterwards

Other researchers now use our methods</gtr:impact><gtr:outcomeId>5457ce57434c47.65631186</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.ffcrelax.com/ffcrelax/ffc2011/mainpage.php?folder=program&amp;page=index.php</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>50837CBE-5DEE-40F2-A890-6E6FAF674C12</gtr:id><gtr:impact>A press release written to share a research success

Over 30 reports in the national and international media picked up this press release. Interviews resulted on local radio.</gtr:impact><gtr:outcomeId>5457da650dcbd5.30821599</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.york.ac.uk/news-and-events/news/2009/medical-diagnosis/</gtr:url><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Huddersfield Hyperpolarisation Meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0B69837B-AEEE-403F-8110-F574B6B73680</gtr:id><gtr:impact>Series of presentations detailing aspects of hyperpolarisation</gtr:impact><gtr:outcomeId>58c18b99801022.58297921</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Euromar, Florence, Italy.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>19B97EF8-E654-4768-80FE-141BEAA79522</gtr:id><gtr:impact>Over 100 people attended a presentation which sparked questions and discussion afterwards

Over 15 research groups worldwide have adopted our methods</gtr:impact><gtr:outcomeId>5457c904eb2a25.02096540</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.euromar.org/about.html</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Wellcome Trust Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>07AAA8ED-8566-4CD5-B130-23F4CAF458A8</gtr:id><gtr:impact>To inform on progress towards the clinical uptake of SABRE</gtr:impact><gtr:outcomeId>58c18982928d85.25002784</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Intermediary Metabolism in Cancer meeting, Dallas USA.</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>702F5AAA-6172-4812-8A58-FEAB7CD48810</gtr:id><gtr:impact>Over 100 people attended a presentation which sparked questions and discussion afterwards

Over 15 research groups worldwide have adopted our methods. This includes groups at Johns Hopkins, UT Southwestern Medical Centre, and the University Medical Center Freiburg</gtr:impact><gtr:outcomeId>5457c872c15407.66440914</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.utsouthwestern.edu/edumedia/edufiles/departments_centers/airc/annual-symposium-202010.pdf</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3A022A6F-5219-4D9D-B7F2-5C0C10A5FB43</gtr:id><gtr:impact>Information shared with public

Research progresses towards clinical use</gtr:impact><gtr:outcomeId>5457db381926f3.23947924</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.york.ac.uk/news-and-events/news/2010/research/hyperpolarisation/</gtr:url><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New national centre to transform medical imaging</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>93B82541-1264-4272-9984-8B66D99C9F39</gtr:id><gtr:impact>Detail new funding stream

A new &amp;pound;6.8 million research centre based across two Yorkshire universities will aim to transform diagnosis and treatment of patients suffering from cancer, heart disease and musculoskeletal diseases with the help of new medical imaging facilities to be created at Leeds Teaching Hospitals and the University of York.</gtr:impact><gtr:outcomeId>5457ddaf587fa3.72206078</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.york.ac.uk/news-and-events/news/2014/medical-imaging-centre/</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Gordon Conference, In Vivo Magnetic Resonance</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E525A571-C1DF-4A40-BF41-1A8D89AE161C</gtr:id><gtr:impact>Over 100 people attended a presentation which sparked questions and discussion afterwards 

Over 15 research groups worldwide have adopted our methods</gtr:impact><gtr:outcomeId>5457d950238a84.87095980</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.grc.org/programs.aspx?year=2014&amp;program=invivo</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New scanning technology aims to achieve quicker diagnosis of disease</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D2017B8D-B486-4BBF-8169-1108FD18ABEC</gtr:id><gtr:impact>New scanning technology aims to achieve quicker diagnosis of disease. Groundbreaking research taking place at the University of York could lead to Alzheimer's disease being diagnosed in minutes using a simple brain scan. Scientists are working on new technology that could revolutionise the way in which Magnetic Resonance Imaging (MRI) scans are used to view the molecular events behind diseases like Alzheimer's, without invasive procedure, by increasing the sensitivity of an average hospital scanner by 200,000 times.

The technology underpinning this project, SABRE (Signal Amplification by Reversible Exchange), has received a &amp;pound;3.6m Strategic Award from the Wellcome Trust to fund a team of seven post-doctoral researchers from this month.

on-going</gtr:impact><gtr:outcomeId>5457de8123b675.35675899</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.york.ac.uk/chym/news/2012/scanning/</gtr:url><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>65000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GlaxoSmithKline (GSK)</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>509991C7-82BB-47A4-8FB3-12AF40DFE420</gtr:id><gtr:outcomeId>r-9628898892.206045068bdeea</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4360000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Capital Awards Scheme</gtr:description><gtr:end>2016-11-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>092506/B/10/Z</gtr:fundingRef><gtr:id>D25E4F5E-9E45-466D-B45B-35947F762E05</gtr:id><gtr:outcomeId>5ee181b25ee181c6</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>3500000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Strategic Awards Scheme</gtr:description><gtr:end>2017-11-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>098335/Z/12/Z</gtr:fundingRef><gtr:id>D4188F98-23D5-4077-B735-6C76C72B3A37</gtr:id><gtr:outcomeId>5ee150b65ee150ca</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>65000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>GlaxoSmithKline (GSK)</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:fundingRef>STU029361</gtr:fundingRef><gtr:id>155E391E-97FC-4998-94BC-8C5FFBB5E572</gtr:id><gtr:outcomeId>5ec2054e5ec20562</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The findings of this award formed the basis to allow the University to establish a spinout.</gtr:description><gtr:firstYearOfImpact>2013</gtr:firstYearOfImpact><gtr:id>481DAFA7-1079-4E71-A8AF-619076736C4A</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>544fe7ea62adb9.48836409</gtr:outcomeId><gtr:sector>Healthcare</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>An NMR method is presented having enhanced sensitivity on a compound comprising hyperpolarizable nuclei, in particular applying enhanced PHIP. Polarization is thereby transferred from a prepared fluid, which is enriched with symmetric molecules of a particular spin state (e.g. para-hydrogen enriched), directly to the hyperpolarizable nuclei of a compound, without altering the chemical identity of the compound in this process. Spin transfer is achieved using a template having sites of ordered environment, and the fluid and the compound are brought together in the presence of the template. Polarization transfer to the hyperpolarizable nuclei of the compound is thereby easier to perform and can be applied to a broader scope of compounds.</gtr:description><gtr:grantRef>EP/H029575/1</gtr:grantRef><gtr:id>09DA1D86-5238-429D-910B-61DA87E96FEC</gtr:id><gtr:impact>This product has been licensed to Bruker BioSpin</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>544fe0ba7c3ae5.99475997</gtr:outcomeId><gtr:patentId>US 8154284 B2</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Hyperpolaritzation of compounds for NMR, in particular by means of PHIP</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>The invention relates to a device (1, 21, 31, 41, 64) for the preparation and measurement of a nuclear spin resonance (NMR) measurement sample (10), including-a flow-through NMR probehead (2), with a first tube (3) and a second tube (14) each for the supply and removal of a liquid NMR measurement sample (10),-at least one chamber (4, 22, 32) which is connected to one of the tubes (3, 14),-a sample inlet (5) for introducing the liquid measurement sample (10) into the device (1, 21, 31, 41, 64), wherein at least one chamber (4, 22, 32) has at least one connection for increasing (9, 24, 25, 42, 43, 46, 47) and releasing (8, 23, 27, 48 a , 48 b) the gas pressure, and in which at least one chamber (4, 22, 32) comprises means for mixing the liquid measurement sample (10) contained in the chamber (4, 22, 32) with a gas With the inventive device it is possible to reduce the measurement sample consumption when doing an NMR spectroscopic measurement on liquid measurement samples to which spin order can be catalytically transferred.</gtr:description><gtr:grantRef>EP/H029575/1</gtr:grantRef><gtr:id>3CDA154A-BB1D-4605-BEA5-4BDCF3BC99EA</gtr:id><gtr:impact>This has been licensed to Bruker BioSpin</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>544fe11bb01846.10776427</gtr:outcomeId><gtr:patentId>US 8766631 B2</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>NMR measurement apparatus with flow-through probehead</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>An NMR experiment on hyperpolarizable magnetic nuclei of substrate molecules in a living human or animal body, involves polarizing the substrate molecules by non-hydrogenating para-hydrogen induced polarization (=NH-PHIP) into a singlet/pseudo singlet state in low magnetic field and injecting the substrate molecules into the living body, the body or a part thereof being previously located inside a magnet at low magnetic field. The magnet is switched on to high magnetic field, and in at least part of the substrate molecules, the singlet state/pseudo singlet state is converted into observable magnetization. An MRI or MRS measurement is carried out with the living body or the part thereof, collecting data from the substrate molecules. The NMR experiment is well applicable on hyperpolarized nuclei within a patient, with reduced losses of magnetization due to relaxation processes.</gtr:description><gtr:grantRef>EP/H029575/1</gtr:grantRef><gtr:id>5E650FF4-6148-47BE-9CA9-85874CCF0EE2</gtr:id><gtr:impact>We hope that this patent will be used by Bruker BioSpin.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>544fe034579c28.14380308</gtr:outcomeId><gtr:patentId>8825132</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>Field Cycling Method for Magnetic Resonance</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>There is described a method of selective observation of non-hydrogenative para- hydrogen induced polarisation (NH-PHIP) as enhanced magnetic resonance signals which comprises separating the thermal and longitudinal spin order states. There is also described a template comprising [Ir(COD)(NHC)(Py)]+, and analogues thereof, for use in a PHIP magnetic resonance technique and a method for its preparation.</gtr:description><gtr:grantRef>EP/H029575/1</gtr:grantRef><gtr:id>42DF36CC-071E-4C60-BB5D-83B5BD69FBDD</gtr:id><gtr:impact>We are working with Bruker BipSpin on the application.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>544fe17c2ddab9.46712883</gtr:outcomeId><gtr:patentId>WO 2010067076</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Pulse sequencing with hyperpolarisable nuclei</gtr:title><gtr:yearProtectionGranted>2010</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:keyFindingsOutput><gtr:description>The work undertaken as part of this follow on fund bid allowed the ground work to be prepared to form the University spinout Hypernetics Imaging Ltd. The commerical case was developed through external consulation. We also worked towards to collection of in vivo data</gtr:description><gtr:exploitationPathways>Our findings will be used by Hypernetics going forward.</gtr:exploitationPathways><gtr:id>B1FC273E-3D05-4B6E-ADD9-B44EE5809C3A</gtr:id><gtr:outcomeId>544fdcff1637a4.95852384</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals,Manufacturing, including Industrial Biotechology,Other</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>We worked with Bruker BioSpin to produce a device to make parahydrogen</gtr:description><gtr:id>3AB73710-8E9E-4FC4-B3DF-9FC0D8F021DF</gtr:id><gtr:impact>The device is being used by a number of researchers to help support hyperpolarisation studies aligned to clinical MRI.</gtr:impact><gtr:outcomeId>544fe3ec1aa571.42141390</gtr:outcomeId><gtr:title>Parahydrogen Generator</gtr:title><gtr:type>New/Improved Technique/Technology</gtr:type><gtr:url>http://www.bruker.com/products/mr/nmr/accessories/hyperpolarization/parahydrogen-generator/overview.html</gtr:url><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>HYPERNETICS IMAGING LIMITED</gtr:companyName><gtr:description>Currently company holds the patents associated with SABRE and seeks to develop their use.</gtr:description><gtr:id>0ADB0776-002A-47E3-9BCD-B93EAAA8AD8D</gtr:id><gtr:impact>Currently seeking investment</gtr:impact><gtr:outcomeId>5457e1c2097c56.89598411</gtr:outcomeId><gtr:yearCompanyFormed>2013</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>7D8B4C0F-7889-4D46-8D2E-95491348FA51</gtr:id><gtr:title>The reaction of an iridium PNP complex with parahydrogen facilitates polarisation transfer without chemical change.</gtr:title><gtr:parentPublicationTitle>Dalton transactions (Cambridge, England : 2003)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd063d1246c4ef7fc0641cb70a688b0d"><gtr:id>dd063d1246c4ef7fc0641cb70a688b0d</gtr:id><gtr:otherNames>Holmes AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1477-9226</gtr:issn><gtr:outcomeId>56c5ff386e2a94.06099919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31490E3D-58C1-4E93-8F7F-F31E65482882</gtr:id><gtr:title>Utilization of SABRE-derived hyperpolarization to detect low-concentration analytes via 1D and 2D NMR methods.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec635d5532f80cf2c544fe67734ec2be"><gtr:id>ec635d5532f80cf2c544fe67734ec2be</gtr:id><gtr:otherNames>Lloyd LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>541b15d45ae799.53980682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05412872-FB73-47AD-9F4D-F72A3CED6035</gtr:id><gtr:title>Utilisation of water soluble iridium catalysts for signal amplification by reversible exchange.</gtr:title><gtr:parentPublicationTitle>Dalton transactions (Cambridge, England : 2003)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a43367fbc987f1ec954721327a15270d"><gtr:id>a43367fbc987f1ec954721327a15270d</gtr:id><gtr:otherNames>Fekete M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1477-9226</gtr:issn><gtr:outcomeId>56c5ff37ebce02.81967697</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CE23930F-F3B6-4099-A109-938F118F3EA8</gtr:id><gtr:title>Hyperpolarisation through reversible interactions with parahydrogen</gtr:title><gtr:parentPublicationTitle>Catal. Sci. Technol.</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2de7dcc4cef09b9436fe5c968c43c627"><gtr:id>2de7dcc4cef09b9436fe5c968c43c627</gtr:id><gtr:otherNames>Lloyd L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>doi_55f95c95ce5d5f26</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>877E835E-151C-4753-92DD-104E11963B9F</gtr:id><gtr:title>Iridium(III) hydrido N-heterocyclic carbene-phosphine complexes as catalysts in magnetization transfer reactions.</gtr:title><gtr:parentPublicationTitle>Inorganic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a43367fbc987f1ec954721327a15270d"><gtr:id>a43367fbc987f1ec954721327a15270d</gtr:id><gtr:otherNames>Fekete M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0020-1669</gtr:issn><gtr:outcomeId>541b1673af2425.84581100</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AFA13CB2-136B-41FA-A1D7-A38C498ABCA7</gtr:id><gtr:title>Catalytic Transfer of Magnetism using a Neutral Iridium Phenoxide Complex.</gtr:title><gtr:parentPublicationTitle>Organometallics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26a3c0754a83521287de942543016943"><gtr:id>26a3c0754a83521287de942543016943</gtr:id><gtr:otherNames>Ruddlesden AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0276-7333</gtr:issn><gtr:outcomeId>5675fdff84b06</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>891D34DE-7C52-49ED-95EB-FAC913436844</gtr:id><gtr:title>The theory and practice of hyperpolarization in magnetic resonance using parahydrogen.</gtr:title><gtr:parentPublicationTitle>Progress in nuclear magnetic resonance spectroscopy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/974200e05f730cdc6460e18bfbe150d8"><gtr:id>974200e05f730cdc6460e18bfbe150d8</gtr:id><gtr:otherNames>Green RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0079-6565</gtr:issn><gtr:outcomeId>541b1632cf02e2.51074390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97DE5657-5F33-41B5-8992-25EC4E33A6DD</gtr:id><gtr:title>Iridium N-heterocyclic carbene complexes as efficient catalysts for magnetization transfer from para-hydrogen.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92566ed87daa534df0a5f27f2be15f14"><gtr:id>92566ed87daa534df0a5f27f2be15f14</gtr:id><gtr:otherNames>Cowley MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>541b17464e1571.83866536</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC8C4A5E-692B-4703-BDB6-F3D8D71DAC82</gtr:id><gtr:title>Improving the hyperpolarization of (31)P nuclei by synthetic design.</gtr:title><gtr:parentPublicationTitle>The journal of physical chemistry. B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6a3f6b96a467ebc77c42ca9a1df3181"><gtr:id>c6a3f6b96a467ebc77c42ca9a1df3181</gtr:id><gtr:otherNames>Burns MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1520-5207</gtr:issn><gtr:outcomeId>56c5ff38240bf3.72675785</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CEBF0CE7-38E5-4AD4-9D10-91A998344405</gtr:id><gtr:title>Deactivation of signal amplification by reversible exchange catalysis, progress towards in vivo application.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/372086874c5d7858c3d4657cd456c1fc"><gtr:id>372086874c5d7858c3d4657cd456c1fc</gtr:id><gtr:otherNames>Mewis RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>56c5ff38495744.11963907</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50CA7229-72D1-4D69-B805-01E84125E8B3</gtr:id><gtr:title>Application of parahydrogen induced polarization techniques in NMR spectroscopy and imaging.</gtr:title><gtr:parentPublicationTitle>Accounts of chemical research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92ffafa9a1798a7879d22ff5e577cb03"><gtr:id>92ffafa9a1798a7879d22ff5e577cb03</gtr:id><gtr:otherNames>Duckett SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0001-4842</gtr:issn><gtr:outcomeId>541b16e24cad77.01867824</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68CD5616-46FF-460D-92DB-D38173C2D317</gtr:id><gtr:title>Facing and Overcoming Sensitivity Challenges in Biomolecular NMR Spectroscopy.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2acb69b4403de66d82ef11cfd0570179"><gtr:id>2acb69b4403de66d82ef11cfd0570179</gtr:id><gtr:otherNames>Ardenkjaer-Larsen JH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>56c5ff907ef319.32251747</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0A4A043-41C9-46DD-9535-D17FC408B887</gtr:id><gtr:title>Correction to Iridium(III) Hydrido N-Heterocyclic Carbene&amp;acirc;??Phosphine Complexes as Catalysts in Magnetization Transfer Reactions</gtr:title><gtr:parentPublicationTitle>Inorganic Chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a43367fbc987f1ec954721327a15270d"><gtr:id>a43367fbc987f1ec954721327a15270d</gtr:id><gtr:otherNames>Fekete M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>541b16553f3bc4.78202621</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91183C59-6DBB-42E1-9CBA-F78B6EE73496</gtr:id><gtr:title>Selective detection of hyperpolarized NMR signals derived from para-hydrogen using the Only Para-hydrogen SpectroscopY (OPSY) approach.</gtr:title><gtr:parentPublicationTitle>Journal of magnetic resonance (San Diego, Calif. : 1997)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17abb2d6c4bc453c37ae9532472ff2b5"><gtr:id>17abb2d6c4bc453c37ae9532472ff2b5</gtr:id><gtr:otherNames>Aguilar JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1090-7807</gtr:issn><gtr:outcomeId>541b17f44e97d4.16593688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A430C63-8B0B-4863-9B40-E3FDE323BE59</gtr:id><gtr:title>Improving NMR and MRI sensitivity with parahydrogen.</gtr:title><gtr:parentPublicationTitle>Topics in current chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/92ffafa9a1798a7879d22ff5e577cb03"><gtr:id>92ffafa9a1798a7879d22ff5e577cb03</gtr:id><gtr:otherNames>Duckett SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:isbn>978-3-642-39727-1</gtr:isbn><gtr:issn>0340-1022</gtr:issn><gtr:outcomeId>541b16b4c8ab45.36658111</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DDCD4A7-0BAC-4A94-9A62-4E024FA61A32</gtr:id><gtr:title>Strategies for the hyperpolarization of acetonitrile and related ligands by SABRE.</gtr:title><gtr:parentPublicationTitle>The journal of physical chemistry. B</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/372086874c5d7858c3d4657cd456c1fc"><gtr:id>372086874c5d7858c3d4657cd456c1fc</gtr:id><gtr:otherNames>Mewis RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1520-5207</gtr:issn><gtr:outcomeId>doi_55f95c95ce453e50</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE34EE7D-BA0C-45BC-B5DC-20710BCE83C8</gtr:id><gtr:title>A continuous-flow, high-throughput, high-pressure parahydrogen converter for hyperpolarization in a clinical setting.</gtr:title><gtr:parentPublicationTitle>NMR in biomedicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91541c676c18803ed0744072296de638"><gtr:id>91541c676c18803ed0744072296de638</gtr:id><gtr:otherNames>H?vener JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0952-3480</gtr:issn><gtr:outcomeId>541b16070c00b7.45092856</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B5216868-08C0-4F39-9C2F-693E3D774766</gtr:id><gtr:title>Investigating pyridazine and phthalazine exchange in a series of iridium complexes in order to define their role in the catalytic transfer of magnetisation from-hydrogen.</gtr:title><gtr:parentPublicationTitle>Chemical science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/29cc1e04eca8ec0aab46331426640051"><gtr:id>29cc1e04eca8ec0aab46331426640051</gtr:id><gtr:otherNames>Appleby KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-6520</gtr:issn><gtr:outcomeId>5675fe0542fb8</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/H029575/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>FB535BD0-E265-4C0A-8532-32DCB83A3951</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Tools, technologies &amp; methods</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>A759BB04-AFFE-4780-BD31-9A2707BC44BA</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Medical Imaging</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>